TAKARA BIO INC.【JP:4974】Income statement

Market cap

¥138.1B

P/E ratio

-15.3x

Takara Bio develops and manufactures biotechnology products including research reagents, PCR instruments, and gene therapy treatments for universities, research institutions, and companies worldwide.

Summary Financials Dividends History Ownership Workforce

Income statement Balance sheet Cash flow Other

	2012/03	2013/03	2014/03	2015/03	2016/03	2017/03	2018/03	2019/03	2020/03	2021/03	2022/03	2023/03	2024/03	2025/03
Revenue	19,578	20,564	23,905	25,969	29,729	29,375	32,312	35,841	34,565	46,086	67,699	78,142	43,505	45,039
Revenue growth (%)	-
Cost of revenue	-	-	-	12,142	13,405	12,422	13,657	15,155	13,459	14,214	18,488	33,377	16,597	18,972
Gross profit	-	-	-	13,827	16,323	16,952	18,655	20,685	21,105	31,872	49,211	44,765	26,908	26,067
Gross margin (%)	-	-	-
Operating margin (%)	-	-	-
Operating expenses	-	-	-	11,524	13,655	13,749	15,099	15,221	14,830	17,919	20,309	24,224	23,905	23,804
Operating income	-	-	-	2,302	2,667	3,202	3,555	5,463	6,274	13,952	28,902	20,541	3,003	2,263
Income before tax	1,829	1,965	2,240	2,772	3,301	3,579	3,861	5,665	6,347	14,159	28,459	20,682	3,405	2,592
Pretax margin (%)	9.3	9.6	9.4	10.7	11.1	12.2	11.9	15.8	18.4	30.7	42	26.5	7.8	5.8
Provision for income taxes	-	-	-	1,521	1,565	1,449	1,023	1,149	1,601	3,971	7,624	5,176	1,343	910
Effective tax rate (%)	-	-	-
Net income	558	1,422	1,316	963	1,340	1,356	2,338	3,673	3,831	9,581	19,908	16,047	1,510	1,087
Net income margin (%)
Earnings per share	9.06	12.94	12.5	8.01	11.08	11.24	19.39	30.38	31.72	79.29	164.84	132.97	12.3	8.65
Diluted EPS	-	12.89	12.45	-	-	-	-	-	-	-	-	-	-	-
Dividend per share	-	-	-	-	-	-	-	-	8	16	33	42	17	17
EBITDA	-	-	-
EBITDA margin (%)	-	-	-

Raw aggregated data